Modality
Vaccine
MOA
JAK1/2i
Target
Nectin-4
Pathway
STING
SCLCCervical Ca
Development Pipeline
Preclinical
~Jun 2021
→ ~Sep 2022
Phase 1
~Dec 2022
→ ~Mar 2024
Phase 2
Jun 2024
→ Feb 2029
Phase 2Current
NCT08687296
59 pts·SCLC
2024-06→2029-02·Terminated
59 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-02-192.9y awayPh2 Data· SCLC
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P2
Termina…
Catalysts
Ph2 Data
2029-02-19 · 2.9y away
SCLC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08687296 | Phase 2 | SCLC | Terminated | 59 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| ION-3857 | Ionis | Preclinical | Nectin-4 | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 |